A Review on Steroidal 5α-Reductase Inhibitors for Treatment of Benign Prostatic Hyperplasia

Author(s): J. Sun, H. Xiang, L.-L. Yang, J.-B. Chen.

Journal Name: Current Medicinal Chemistry

Volume 18 , Issue 23 , 2011

Submit Manuscript
Submit Proposal


Benign prostatic hyperplasia (BPH) is a kind of common noncancerous prostate gland enlargement with growing tendency in recent years. 5α-reductase is the key enzyme responsible for dihydrotestosterone biosynthesis and has been considered as an important target for designing inhibitors as potent therapeutic agents for BPH. Finasteride, the first steroidal 5α-reductase inhibitor, has been marketed worldwide as a drug for BPH. During these years, many other novel types of 5α-reductase inhibitors are being studied. This review summarizes recent advancement in steroidal 5α-reductase inhibitors.

Keywords: 5α-Reductase, 5α-reductase inhibitors, benign prostatic hyperplasia, dihydrotestosterone, steroid, finasteride, azasteroid, 3-carboxylic acid, pregnane derivatives, natural products

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Page: [3576 - 3589]
Pages: 14
DOI: 10.2174/092986711796642517
Price: $58

Article Metrics

PDF: 4